296 related articles for article (PubMed ID: 26824319)
21. Suppression of microphthalmia-associated transcription factor, but not NF-kappa B sensitizes melanoma specific cell death.
Mokhamatam RB; Sahoo BK; Manna SK
Apoptosis; 2016 Aug; 21(8):928-40. PubMed ID: 27325430
[TBL] [Abstract][Full Text] [Related]
22. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.
Gilmartin AG; Bleam MR; Groy A; Moss KG; Minthorn EA; Kulkarni SG; Rominger CM; Erskine S; Fisher KE; Yang J; Zappacosta F; Annan R; Sutton D; Laquerre SG
Clin Cancer Res; 2011 Mar; 17(5):989-1000. PubMed ID: 21245089
[TBL] [Abstract][Full Text] [Related]
23. A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF
Smith MP; Rana S; Ferguson J; Rowling EJ; Flaherty KT; Wargo JA; Marais R; Wellbrock C
Pigment Cell Melanoma Res; 2019 Mar; 32(2):280-291. PubMed ID: 30277012
[TBL] [Abstract][Full Text] [Related]
24. Trametinib (GSK1120212).
Zeiser R; Andrlová H; Meiss F
Recent Results Cancer Res; 2018; 211():91-100. PubMed ID: 30069762
[TBL] [Abstract][Full Text] [Related]
25. P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.
Najem A; Krayem M; Salès F; Hussein N; Badran B; Robert C; Awada A; Journe F; Ghanem GE
Eur J Cancer; 2017 Sep; 83():154-165. PubMed ID: 28738256
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
[TBL] [Abstract][Full Text] [Related]
27. Small-molecule inhibitors of ERK-mediated immediate early gene expression and proliferation of melanoma cells expressing mutated BRaf.
Samadani R; Zhang J; Brophy A; Oashi T; Priyakumar UD; Raman EP; St John FJ; Jung KY; Fletcher S; Pozharski E; MacKerell AD; Shapiro P
Biochem J; 2015 May; 467(3):425-38. PubMed ID: 25695333
[TBL] [Abstract][Full Text] [Related]
28. Suppression of NF-kappaB activity by parthenolide induces X-ray sensitivity through inhibition of split-dose repair in TP53 null prostate cancer cells.
Watson C; Miller DA; Chin-Sinex H; Losch A; Hughes W; Sweeney C; Mendonca MS
Radiat Res; 2009 Apr; 171(4):389-96. PubMed ID: 19397439
[TBL] [Abstract][Full Text] [Related]
29. BIK is involved in BRAF/MEK inhibitor induced apoptosis in melanoma cell lines.
Borst A; Haferkamp S; Grimm J; Rösch M; Zhu G; Guo S; Li C; Gao T; Meierjohann S; Schrama D; Houben R
Cancer Lett; 2017 Sep; 404():70-78. PubMed ID: 28720543
[TBL] [Abstract][Full Text] [Related]
30. The role of MITF and Mcl-1 proteins in the antiproliferative and proapoptotic effect of ciprofloxacin in amelanotic melanoma cells: In silico and in vitro study.
Beberok A; Rok J; Rzepka Z; Marciniec K; Boryczka S; Wrześniok D
Toxicol In Vitro; 2020 Aug; 66():104884. PubMed ID: 32437906
[TBL] [Abstract][Full Text] [Related]
31. Parthenolide induces caspase-independent and AIF-mediated cell death in human osteosarcoma and melanoma cells.
D'Anneo A; Carlisi D; Lauricella M; Emanuele S; Di Fiore R; Vento R; Tesoriere G
J Cell Physiol; 2013 May; 228(5):952-67. PubMed ID: 22688575
[TBL] [Abstract][Full Text] [Related]
32. MITF Modulates Therapeutic Resistance through EGFR Signaling.
Ji Z; Erin Chen Y; Kumar R; Taylor M; Jenny Njauw CN; Miao B; Frederick DT; Wargo JA; Flaherty KT; Jönsson G; Tsao H
J Invest Dermatol; 2015 Jul; 135(7):1863-1872. PubMed ID: 25789707
[TBL] [Abstract][Full Text] [Related]
33. Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A.
Mazzio EA; Soliman KFA
Cancer Genomics Proteomics; 2018; 15(5):349-364. PubMed ID: 30194076
[TBL] [Abstract][Full Text] [Related]
34. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
35. 1-Benzyl-indole-3-carbinol is a highly potent new small molecule inhibitor of Wnt/β-catenin signaling in melanoma cells that coordinately inhibits cell proliferation and disrupts expression of microphthalmia-associated transcription factor isoform-M.
Kundu A; Khouri MG; Aryana S; Firestone GL
Carcinogenesis; 2017 Dec; 38(12):1207-1217. PubMed ID: 29028954
[TBL] [Abstract][Full Text] [Related]
36. MEK inhibition remodels the active chromatin landscape and induces SOX10 genomic recruitment in BRAF(V600E) mutant melanoma cells.
Fufa TD; Baxter LL; Wedel JC; Gildea DE; ; Loftus SK; Pavan WJ
Epigenetics Chromatin; 2019 Aug; 12(1):50. PubMed ID: 31399133
[TBL] [Abstract][Full Text] [Related]
37. Physiologically Relevant Oxygen Concentration (6% O
Osrodek M; Hartman ML; Czyz M
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31461993
[TBL] [Abstract][Full Text] [Related]
38. Cell context-dependent activities of parthenolide in primary and metastatic melanoma cells.
Czyz M; Lesiak-Mieczkowska K; Koprowska K; Szulawska-Mroczek A; Wozniak M
Br J Pharmacol; 2010 Jul; 160(5):1144-57. PubMed ID: 20590608
[TBL] [Abstract][Full Text] [Related]
39. Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells.
Kurata K; Onoda N; Noda S; Kashiwagi S; Asano Y; Hirakawa K; Ohira M
Int J Oncol; 2016 Dec; 49(6):2303-2308. PubMed ID: 27748799
[TBL] [Abstract][Full Text] [Related]
40. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]